Legend Biotech taps Novartis veteran Zhang as CEO

Legend Biotech on Tuesday appointed longtime Novartis executive Ingrid Zhang as its CEO, effective immediately, banking on an ​industry veteran to steer its expansion beyond blockbuster ‌cancer therapy Carvykti.

Reuters • Sep 15, 2026

Legend Biotech Appoints Ingrid Zhang as Chief Executive Officer

BRIDGEWATER, N.J., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) ("Legend Biotech" or the "Company"), a global leader in cell therapy, today announced that its Board of Directors has appointed Ingrid Zhang as Chief Executive Officer, effective September 15, 2026.

GlobeNewsWire • Sep 15, 2026

Legend Biotech is tapping a Novartis executive to run the cell-therapy maker, ending a nearly two-month search that began when former CEO Ying Huang resigned in July

Ingrid Zhang will take the helm of the cancer therapy company, filling a post vacant since its previous CEO abruptly resigned in July.

WSJ • Sep 15, 2026

Legend Biotech to Present Updated Long-Term and Real-World Evidence from CARVYKTI Clinical Program at the International Myeloma Society Annual Meeting

Updated long-term follow-up data will be presented from CARTITUDE-2 Cohort A in patients with lenalidomide-refractory multiple myeloma after 1-3 prior lines of therapy Real-world evidence and post-authorization safety study findings will also be presented BRIDGEWATER, N.J., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced that data from CARTITUDE-2 and real-world evidence will be presented at the 23rd International Myeloma Society (IMS) Annual Meeting, taking place September 23-26, 2026, in Glasgow, Scotland.

GlobeNewsWire • Sep 10, 2026

Legend Biotech to Participate in the Morgan Stanley Global Healthcare Conference

BRIDGEWATER N.J., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced that Alan Bash, interim Chief Executive Officer, will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference in New York, NY on Tuesday, September 15, 2026, at 2:35 p.m.

GlobeNewsWire • Sep 1, 2026

Legend's Pipeline Is Starting To Matter

Legend Biotech is transitioning from a capital-intensive biotech to a profitable, CARVYKTI-driven commercial cell therapy company. Q2 results highlight 52% YoY revenue growth, strong international CARVYKTI momentum, and a swing to $57.7M operating income, signaling sustainable profitability. CARVYKTI's 50% YoY sales growth is driven by earlier-line adoption and global expansion, with over 70% use now in 2L–4L settings.

Seeking Alpha • Aug 12, 2026

Legend Biotech Gains 6% on Q2 Earnings Beat as Adjusted EPS Doubles Consensus

Shares of Legend Biotech (NASDAQ:LEGN | LEGN Price Prediction) are climbing 6% to $21.88 Tuesday midday after the company reported Q2 2026 results that paired a solid revenue beat with the first quarter of company-wide profitability in its history.

24/7 Wall Street • Aug 11, 2026

Legend Biotech Q2 Earnings Call Highlights

Legend Biotech NASDAQ: LEGN reported second-quarter 2026 results marked by continued global growth for CARVYKTI and the company's first quarter of company-wide profitability on both an IFRS and adjusted basis, management said during its earnings call.

MarketBeat • Aug 11, 2026

Legend Biotech Corporation (LEGN) Q2 2026 Earnings Call Transcript

Legend Biotech Corporation (LEGN) Q2 2026 Earnings Call Transcript

Seeking Alpha • Aug 11, 2026

Top 3 Health Care Stocks You'll Regret Missing This Quarter

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Benzinga • Aug 4, 2026